Curriculum vitae - Radboud University Portal · Curriculum vitae 1 ... Smith MR, Saad F, Rathkopf...

Curriculum vitae

1 Update 4 oktober 2017

Naam Prof. dr. Peter F.A. Mulders Geboortedatum 31 mei 1962 Adres Bovensteweg 6, 6585 KC Mook Naam echtgenote Cindy Hugen Functie Staflid Medische staf urologie Afdelingshoofd Employer Radboud universitair medisch centrum Afdeling Urologie – route 610 Geert Grooteplein Zuid 10 6525 GA Nijmegen [email protected] Tel. +31 (0)24 - 361 3735 BIG-nr. 59022906501 Opleiding 1980-1988 Studie Geneeskunde, Medische Faculteit Universiteit van Nijmegen, Nederland Professionele ervaring 2006- Hoogleraar algemene Urologie, Universitair Medisch Centrum St Radboud, Nijmegen 2004- Afdelingshoofd, afdeling Urologie, Universitair Medisch Centrum St Radboud, Nijmegen 2002-2004 Waarnemend Hoofd, afdeling Urologie, Universitair Medisch Centrum St Radboud,

Nijmegen 10/1997- Uroloog, afdeling Urologie, Universitair Medisch Centrum St Radboud, Nijmegen 1995-1997 Post Doctoraal Fellowship, UCLA, Los Angeles, USA. Nederlandse Kanker Bestrijding KWF (mentor prof. dr. F.H. Schröder): Clinical Research

Fellowship in Urological Oncology, Department of Urology (afdelingshoofd Prof. J. deKernion), Division of Oncological Urology and Immunotherapy laboratory (afdelingshoofd: Prof. A. Belldegrun).

1991-1994 Promotie: 'Prognostic Factors in Urological Tumors' (promotor prof. dr. F.M.J. Debruyne)

1992-1996 Opleiding Urologie, afdeling Urologie, Universitair Medisch Centrum St Radboud, Nijmegen. (afdelingshoofd prof.dr. F.M.J. Debruyne), CWZ, Nijmegen (dr. H. Karthaus)

1989-1992 Voor-opleiding Heelkunde, IKAZIA Ziekenhuis Rotterdam (afdelingshoofd dr. A.P. Brinkhorst en dr. H.F. Veen)

1988-1989 Militaire dienst, arts Prijzen 2004 European Association of Urology Matula Award 2016 Kidney Cancer Association P.H.M. de Mulder Award at the Eleventh European International Kidney Cancer Symposium

mailto:[email protected]

Curriculum vitae


Publicaties

1. Hendriks RJ, van der Leest MMG, Dijkstra S, Barentsz JO, Van Criekinge W, Hulsbergen-van de Kaa

CA, Schalken JA, Mulders PFA, van Oort IM. A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection. Prostate. 2017 Oct;77(14):1401-1407.

2. d: de Bitter T, van de Water C, van den Heuvel C, Zeelen C, Eijkelenboom A, Tops B, Oosterwijk E, Kolev D, Mulders P, Ter Laan M, van Lith S, Leenders W. Profiling of the metabolic transcriptome via single molecule molecular inversion probes. Sci Rep. 2017 Sep 12;7(1):11402.

3. Hekman MCH, Boerman OC, Bos DL, Massuger LFAG, Weil S, Grasso L, Rybinski KA, Oosterwijk E, Mulders PFA, Rijpkema M. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality Imaging. Mol Pharm. 2017 Aug 30.

4. van Oostenbrugge TJ, Langenhuijsen JF, Overduin CG, Jenniskens SF, Mulders PFA, Fütterer JJ. Percutaneous MR Imaging-Guided Cryoablation of Small Renal Masses in a 3-T Closed-Bore MR Imaging Environment: Initial Experience. J Vasc Interv Radiol. 2017 Aug;28(8):1098-1107.e1.

5. Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles J, Efstathiou E, Kantoff PW, Mulders PFA, Saad F, Chi KN. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017 Jul 25. pii: S1558-7673(17)30211-2.

6. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 Jul;72(1):10-13.

7. Hekman MCH, Rijpkema M, Langenhuijsen JF, Boerman OC, Oosterwijk E, Mulders PFA. Intraoperative Imaging Techniques to Support Complete Tumor Resection in Partial Nephrectomy. Eur Urol Focus. 2017 May 12. pii: S2405-4569(17)30114-1.

8. Hekman MCH, Rijpkema M, Bos DL, Oosterwijk E, Goldenberg DM, Mulders PFA, Boerman OC. Detection of Micrometastases Using SPECT/Fluorescence Dual-Modality Imaging in a CEA-Expressing Tumor Model. J Nucl Med. 2017 May;58(5):706-710.

9. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 Apr;71(4):656-664.

10. Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG. Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst. 2017 Apr 1;109(4).

11. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G, Miller K, Saad F, Bjartell AS, Borre M, Mulders P, Tammela TL, Parli T, Sari S, van Os S, Theeuwes A, Tombal B. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 Feb;71(2):151-154.

12. Barentsz JO, Mulders P, Gerritsen W, Fütterer JJ. Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging. Eur Urol. 2017 Jan;71(1):93-95.

Curriculum vitae


13. Vrieling A, Kampman E, Knijnenburg NC, Mulders PF, Sedelaar JPM, Baracos VE, Kiemeney LA. Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2016 Dec 4. pii: S2405-4569(16)30167-5.

14. Benoist GE, Hendriks RJ, Mulders PF, Gerritsen WR, Somford DM, Schalken JA, van Oort IM, Burger DM, van Erp NP. Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide. Clin Pharmacokinet. 2016 Nov;55(11):1369-1380. Review.

15. Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. Eur Urol. 2016 Nov;70(5):740-748. Epub 2016 Apr 20.

16. Hekman MC, Boerman OC, de Weijert M, Bos DL, Oosterwijk E, Langenhuijsen JF, Mulders PF, Rijpkema M. Targeted Dual-Modality Imaging in Renal Cell Carcinoma: An Ex Vivo Kidney Perfusion Study. Clin Cancer Res. 2016 Sep 15;22(18):4634-42. Epub 2016 Apr 21.

17. Gayet M, van der Aa A, Schmitz P, Beerlage HP, Schrier BP, Mulders PF, Mischi M, Wijkstra H. 3D Navigo™ versus TRUS-guided prostate biopsy in prostate cancer detection. World J Urol. 2016 Sep;34(9):1255-60. Epub 2016 Feb 4.

18. Gayet M, Mannaerts CK, Nieboer D, Beerlage HP, Wijkstra H, Mulders PFA, Roobol MJ. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort. Eur Urol Focus. 2016 Aug 4. pii: S2405-4569(16)30107-9.

19. Lardas M, Stewart F, Scrimgeour D, Hofmann F, Marconi L, Dabestani S, Bex A, Volpe A, Canfield SE, Staehler M, Hora M, Powles T, Merseburger AS, Kuczyk MA, Bensalah K, Mulders PF, Ljungberg B, Lam TB. Systematic Review of Surgical Management of Nonmetastatic Renal Cell Carcinoma with Vena Caval Thrombus. Eur Urol. 2016 Aug;70(2):265-80. Epub 2015 Dec 23.

20. Dijkstra S, Witjes WP, Roos EP, Vijverberg PL, Geboers AD, Bruins JL, Smits GA, Vergunst H, Mulders PF. The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. Springerplus. 2016 May 17;5:653.

21. Muselaers CH, Boers-Sonderen MJ, van Oostenbrugge TJ, Boerman OC, Desar IM, Stillebroer AB, Mulder SF, van Herpen CM, Langenhuijsen JF, Oosterwijk E, Oyen WJ, Mulders PF. Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. Eur Urol. 2016 May;69(5):767-70. Epub 2015 Dec 23.

22. Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 May;69(5):924-32. Epub 2015 Oct 24.

23. Mulders PF. Words of Wisdom. Re: Nivolumab Versus Everolimus in Advanced Renal-Cell Carcinoma. Eur Urol. 2016 Apr;69(4):753-4. Epub 2016 Feb 18.

24. Marconi L, Dabestani S, Lam TB, Hofmann F, Stewart F, Norrie J, Bex A, Bensalah K, Canfield SE, Hora M, Kuczyk MA, Merseburger AS, Mulders PF, Powles T, Staehler M, Ljungberg B, Volpe A. Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. Eur Urol. 2016 Apr;69(4):660-73. Epub 2015 Aug 29.

Curriculum vitae


25. Gayet M, van der Aa A, Beerlage HP, Schrier BP, Mulders PF, Wijkstra H. The value of magnetic resonance imaging and ultrasonography (MRI/US)-fusion biopsy platforms in prostate cancer detection: a systematic review. BJU Int. 2016 Mar;117(3):392-400. Epub 2015 Aug 28.

26. Hendriks RJ, Dijkstra S, Jannink SA, Steffens MG, van Oort IM, Mulders PF, Schalken JA. Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes. Clin Chem Lab Med. 2016 Mar;54(3):483-92.

27. Weight CJ, Mulders PF, Pantuck AJ, Thompson RH. The Role of Adrenalectomy in Renal Cancer. Eur Urol Focus. 2016 Feb;1(3):251-257. Epub 2015 Oct 3.

28. Boers-Sonderen MJ, Mulder SF, Nagtegaal ID, Derikx LA, Wanten GJ, Mulders PF, van der Graaf WT, Hoentjen F, van Herpen CM. Endoscopy in patients with diarrhea during treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitors: Is the cause in the mucosa? Acta Oncol. 2016;55(4):444-8.

29. Gulley JL, Mulders P, Albers P, Banchereau J, Bolla M, Pantel K, Powles T. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm. Oncoimmunology. 2015 Dec 10;5(4):e1107698.

30. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†. Ann Oncol. 2015 Dec;26(12):2392-8. Epub 2015 Sep 14.

31. Derikx LA, Nissen LH, Drenth JP, van Herpen CM, Kievit W, Verhoeven RH, Mulders PF, Hulsbergen-van de Kaa CA, Boers-Sonderen MJ, van den Heuvel TR, Pierik M, Nagtegaal ID, Hoentjen F; Dutch Initiative on Crohn and Colitis; PALGA Group; IBD/RCC Group. Better survival of renal cell carcinoma in patients with inflammatory bowel disease. Oncotarget. 2015 Nov 10;6(35):38336-47.

32. Smith MR, Rathkopf DE, Mulders PF, Carles J, Van Poppel H, Li J, Kheoh T, Griffin TW, Molina A, Ryan CJ. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer. J Urol. 2015 Nov;194(5):1277-84. Epub 2015 Jul 4.

33. Boers-Sonderen MJ, Desar IM, Fütterer JJ, Mulder SF, De Geus-Oei LF, Mulders PF, Van Der Graaf WT, Oyen WJ, Van Herpen CM. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Res. 2015 Oct;35(10):5601-6.

34. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct;68(4):570-7. Epub 2015 May 16.

35. Muselaers CH, Rijpkema M, Bos DL, Langenhuijsen JF, Oyen WJ, Mulders PF, Oosterwijk E, Boerman OC. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. J Urol. 2015 Aug;194(2):532-8. Epub 2015 Feb 14. PubMed PMID: 25686542.

36. Leyten GH, Hessels D, Smit FP, Jannink SA, de Jong H, Melchers WJ, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Schalken JA. Identification of a Candidate Gene Panel for the Early Diagnosis of Prostate Cancer. Clin Cancer Res. 2015 Jul 1;21(13):3061-70. Epub 2015 Mar 18.

Curriculum vitae


37. Mulders PF, De Santis M, Powles T, Fizazi K. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015 Jun;64(6):655-63. Epub 2015 May 30. Review.

38. Ljungberg B, Bensalah K, Canfield S, Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L, Merseburger AS, Mulders P, Powles T, Staehler M, Volpe A, Bex A. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015 May;67(5):913-24. Epub 2015 Jan 21.

39. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb;16(2):152-60. Epub 2015 Jan 16.

40. Oosterwijk-Wakka JC, de Weijert MC, Franssen GM, Leenders WP, van der Laak JA, Boerman OC, Mulders PF, Oosterwijk E. Successful combination of sunitinib and girentuximab in two renal cell carcinoma animal models: a rationale for combination treatment of patients with advanced RCC. Neoplasia. 2015 Feb;17(2):215-24.

41. Merseburger AS, Scher HI, Bellmunt J, Miller K, Mulders PF, Stenzl A, Sternberg CN, Fizazi K, Hirmand M, Franks B, Haas GP, de Bono J, de Wit R. Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int. 2015 Jan;115(1):41-9. Epub 2014 Oct 23.

42. Albiges L, Choueiri T, Escudier B, Galsky M, George D, Hofmann F, Lam T, Motzer R, Mulders P, Porta C, Powles T, Sternberg C, Bex A. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer. Eur Urol. 2015 Jan;67(1):100-10. Epub 2014 May 1.

43. Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, Dumez H, de Santis M, Théodore C, Leahy MG, Chester JD, Verbaeys A, Daugaard G, Wood L, Witjes JA, de Wit R, Geoffrois L, Sengelov L, Thalmann G, Charpentier D, Rolland F, Mignot L, Sundar S, Symonds P, Graham J, Joly F, Marreaud S, Collette L, Sylvester R; European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group; Groupe d'Etude des Tumeurs Urogénitales; National Cancer Research Institute Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; German Association of Urologic Oncology. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015 Jan;16(1):76-86. Epub 2014 Dec 11.

44. Westdorp H, Benoist GE, Schers HJ, van Erp PH, Gerritsen WR, Mulders PF, Kramers C. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge]. Ned Tijdschr Geneeskd. 2015;159:A9250.

45. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov;66(5):815-25. Epub 2014 Mar 6.

46. Dijkstra S, Leyten GH, Jannink SA, de Jong H, Mulders PF, van Oort IM, Schalken JA. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment. Prostate 2014 Sep;74(12):1222-30. Epub 2014 Jul 7.

Curriculum vitae


47. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014 Jul 31;371(5):424-33. Epub 2014 Jun 1.

48. Dijkstra S, Mulders PF, Schalken JA. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem. 2014 Jul;47(10-11):889-96. Epub 2013 Oct 29.

49. Muselaers CH, Stillebroer AB, Rijpkema M, Franssen GM, Oosterwijk E, Mulders PF, Oyen WJ, Boerman OC. Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. J Nucl Med. 2014 Jun;55(6):1035-40. pub 2014 Apr 21.

50. Muselaers CHJ, Oosterwijk E, Bos DL, Oyen WJG, Mulders PFA, Boerman OC. Optimizing Lutetium 177-Anti-Carbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model. Mol Imaging. 2014 Jun 1;13(4):7290201400008.

51. Mulders PF, Molina A, Marberger M, Saad F, Higano CS, Chi KN, Li J, Kheoh T, Haqq CM, Fizazi K. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol. 2014 May;65(5):875-83. Epub 2013 Sep 20. PubMed PMID: 24099659.

52. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, Powles T. Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol. 2014 Apr;65(4):766-77. Epub 2013 Nov 28. Review. PubMed PMID: 24341958.

53. Dijkstra S, Birker IL, Smit FP, Leyten GH, de Reijke TM, van Oort IM, Mulders PF, Jannink SA, Schalken JA. Prostate cancer biomarker profiles in urinary sediments and exosomes. J Urol. 2014 Apr;191(4):1132-8. Epub 2013 Nov 7. PubMed PMID: 24211598.

54. Mulder SF, Bertens D, Desar IM, Vissers KC, Mulders PF, Punt CJ, van Spronsen DJ, Langenhuijsen JF, Kessels RP, van Herpen CM. Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study. BMC Cancer. 2014 Mar 24;14:219. PubMed PMID: 24661373; PubMed Central PMCID: PMC3987809.

55. Colombel M, Heidenreich A, Martínez-Piñeiro L, Babjuk M, Korneyev I, Surcel C, Yakovlev P, Colombo R, Radziszewski P, Witjes F, Schipper R, Mulders P, Witjes WP. Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. Eur Urol. 2014 Mar;65(3):509-11. Epub 2013 Nov 11. PubMed PMID: 24268503.

56. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, van Oort IM, Mulders PF, Hulsbergen-van de Kaa CA, Schalken JA. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2014 Mar;65(3):534-42. Epub 2012 Nov 15. PubMed PMID: 23201468.

57. Kats-Ugurlu G, Oosterwijk E, Muselaers S, Oosterwijk-Wakka J, Hulsbergen-van de Kaa C, de Weijert M, van Krieken H, Desar I, van Herpen C, Maass C, de Waal R, Mulders P, Leenders W. Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments. Neoplasia. 2014 Mar;16(3):221-8. Epub 2014 Apr 13. PubMed PMID: 24726142; PubMed Central PMCID: PMC4094826.

58. Goodman OB Jr, Flaig TW, Molina A, Mulders PF, Fizazi K, Suttmann H, Li J, Kheoh T, de Bono JS, Scher HI. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2014 Mar;17(1):34-9. Epub 2013 Oct 1.

Curriculum vitae


59. Sternberg CN, de Bono JS, Chi KN, Fizazi K, Mulders P, Cerbone L, Hirmand M, Forer D, Scher HI. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014 Feb;25(2):429-34.

60. Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O, Saad F. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol. 2014 Feb;65(2):289-99. Epub 2013 Aug 11. Review.

61. Muselaers CH, Stillebroer AB, Desar IM, Boers-Sonderen MJ, van Herpen CM, de Weijert MC, Langenhuijsen JF, Oosterwijk E, Leenders WP, Boerman OC, Mulders PF, Oyen WJ. Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. J Nucl Med. 2014 Feb;55(2):242-7. Epub 2014 Jan 6.

62. Muselaers CH, Oosterwijk E, Bos DL, Oyen WJ, Mulders PF, Boerman OC. Optimizing lutetium 177-anti-carbonic anhydrase IX radioimmunotherapy in an intraperitoneal clear cell renal cell carcinoma xenograft model. Mol Imaging. 2014;13:1-7.

63. Harland S, Staffurth J, Molina A, Hao Y, Gagnon DD, Sternberg CN, Cella D, Fizazi K, Logothetis CJ, Kheoh T, Haqq CM, de Bono JS, Scher HI; COU-AA-301 Investigators. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy. Eur J Cancer. 2013 Nov;49(17):3648-57. Epub 2013 Aug 22.

64. Basch E, Autio K, Ryan CJ, Mulders P, Shore N, Kheoh T, Fizazi K, Logothetis CJ, Rathkopf D, Smith MR, Mainwaring PN, Hao Y, Griffin T, Li S, Meyers ML, Molina A, Cleeland C. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol. 2013 Nov;14(12):1193-9. Epub 2013 Sep 25.

65. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Reply to John Samuel Banerji's letter to the editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol 2013;63:1101-6. Eur Urol. 2013 Oct;64(4):e83. Epub 2013 Jul 4.

66. Melichar B, Bracarda S, Matveev V, Alekseev B, Ivanov S, Zyryanov A, Janciauskiene R, Fernebro E, Mulders P, Osborne S, Jethwa S, Mickisch G, Gore M, van Moorselaar RJ, Staehler M, Magne N, Bellmunt J; BEVLiN Investigators. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN. Ann Oncol. 2013 Sep;24(9):2396-402. Epub 2013 Jun 26.

67. Stillebroer AB, Franssen GM, Mulders PF, Oyen WJ, van Dongen GA, Laverman P, Oosterwijk E, Boerman OC. ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. Cancer Biother Radiopharm. 2013 Sep;28(7):510-5. Epub 2013 May 22.

68. Stillebroer AB, Boerman OC, Desar IM, Boers-Sonderen MJ, van Herpen CM, Langenhuijsen JF, Smith-Jones PM, Oosterwijk E, Oyen WJ, Mulders PF. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur Urol. 2013 Sep;64(3):478-85. Epub 2012 Aug 21.

69. Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T. Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol. 2013 Aug;40(4):482-91.

70. Gilles R, de Geus-Oei LF, Mulders PF, Oyen WJ. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol. 2013 Aug;31(4):841-6. Epub 2011 Jul 8

Curriculum vitae


71. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Urol Oncol. 2013 Jul;31(5):549-56. Epub 2011 May 10.

72. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur Urol. 2013 Jun;63(6):1101-6. Epub 2013 Feb 21.

73. Oosterwijk-Wakka JC, Boerman OC, Mulders PF, Oosterwijk E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int J Mol Sci. 2013 May 29;14(6):11402-23.

74. Leyten GH, Wierenga EA, Sedelaar JP, van Oort IM, Futterer JJ, Barentsz JO, Schalken JA, Mulders PF. Value of PCA3 to predict biopsy outcome and its potential role in selecting patients for multiparametric MRI. Int J Mol Sci. 2013 May 28;14(6):11347-55.

75. Muselaers S, Mulders P, Oosterwijk E, Oyen W, Boerman O. Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. Immunotherapy. 2013 May;5(5):489-95.

76. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res. 2013 Feb;33(2):553-7.

77. Mulders PF. From genes to metabolomics in renal cell carcinoma translational research. Eur Urol. 2013 Feb;63(2):252-3. Epub 2012 Nov 16.

78. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, Shariat SF, Chun FK. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2013 Feb;63(2):201-9. Epub 2012 Jul 20.

79. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10;368(2):138-48. Epub 2012 Dec 10. Erratum in: N Engl J Med. 2013 Feb 7;368(6):584.

80. Robert G, Jannink S, Smit F, Aalders T, Hessels D, Cremers R, Mulders PF, Schalken JA. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013 Jan;73(2):113-20. Epub 2012 Jun 5.

81. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Dahm P, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of perioperative and quality-of-life outcomes following surgical management of localised renal cancer. Eur Urol. 2012 Dec;62(6):1097-117. Epub 2012 Jul 20. Review.

82. Bex A, Gore M, Mulders P, Sternberg CN. Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care. BJU Int. 2012 Nov;110(9):1289-300. Epub 2012 Mar 30.

83. Escudier B, Eisen T, Porta C, Patard JJ, Khoo V, Algaba F, Mulders P, Kataja V; ESMO Guidelines Working Group. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71.

84. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS; COU-AA-301 Investigators. Abiraterone acetate for treatment of metastatic castration-resistant

Curriculum vitae


prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct;13(10):983-92. Epub 2012 Sep 18. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464. Lancet Oncol. 2014 Aug;15(9):e365.

85. Mulders PF. Current approaches to bone-targeted therapy in genitourinary malignancies. Ther Adv Urol. 2012 Oct;4(5):219-32.

86. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

87. Desar IM, Mulder SF, Mulders PF, van Herpen CM. The complexity of sunitinib dosing in renal cell cancer patients. Transl Androl Urol. 2012 Sep;1(3):194-6.

88. van de Schans SA, Aben KK, Mulders PF, Haanen JB, van Herpen C, Verhoeven RH, Karim-Kos HE, Oosterwijk E, Kiemeney LA. Modest improvement in 20 years of kidney cancer care in the Netherlands. Eur J Cancer. 2012 Aug;48(12):1822-30. Epub 2012 Feb 23.

89. den Deurwaarder ES, Desar IM, Steenbergen EJ, Mulders PF, Wetzels JF, van Herpen CM. Kidney injury during VEGF inhibitor therapy. Neth J Med. 2012 Aug;70(6):267-71.

90. Lütje S, Boerman OC, van Rij CM, Sedelaar M, Helfrich W, Oyen WJ, Mulders PF. Prospects in radionuclide imaging of prostate cancer. Prostate. 2012 Aug 1;72(11):1262-72. Epub 2011 Nov 29.

91. Schellekens AF, Mulders PC, Ellenbroek B, de Jong CA, Buitelaar JK, Cools A, Verkes RJ. Early-onset alcohol dependence increases the acoustic startle reflex. Alcohol Clin Exp Res. 2012 Jun;36(6):1075-83. Epub 2012 Jan 24.

92. MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Cabungcal AM, Royle P, Stewart F, MacLennan G, MacLennan SJ, Canfield SE, McClinton S, Griffiths TR, Ljungberg B, N'Dow J; UCAN Systematic Review Reference Group; EAU Renal Cancer Guideline Panel. Systematic review of oncological outcomes following surgical management of localised renal cancer. Eur Urol. 2012 May;61(5):972-93. Epub 2012 Feb 25. Review. Erratum in: Eur Urol. 2012 Jul;62(1):193.

93. Burger M, Mulders P, Witjes W. Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. Eur Urol. 2012 May;61(5):1070-1. Epub 2012 Feb 1.

94. Escudier B, Osanto S, Ljungberg B, Porta C, Wagstaff J, Mulders P, Gore M, Bex A, Bellmunt J, Bracarda S, Franklin A, Honoré PH, Ravaud A, Steijn Jv, Aziz Z, Akaza H. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat Rev. 2012 Apr;38(2):127-32. Review. PubMed PMID: 21689888.

95. Mulders P, Hawkins R, Nathan P, de Jong I, Osanto S, Porfiri E, Protheroe A, van Herpen CM, Mookerjee B, Pike L, Jürgensmeier JM, Gore ME. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. Eur J Cancer. 2012 Mar;48(4):527-37. Epub 2012 Jan 28.

96. Saad F, Mulders P. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers. Anticancer Agents Med Chem. 2012 Feb;12(2):129-36.

97. Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol. 2012 Feb;61(2):307-16. Epub 2011 Oct 30. Review.

98. Dulos J, Carven GJ, van Boxtel SJ, Evers S, Driessen-Engels LJ, Hobo W, Gorecka MA, de Haan AF, Mulders P, Punt CJ, Jacobs JF, Schalken JA, Oosterwijk E, van Eenennaam H, Boots AM. PD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer. J Immunother. 2012 Feb-Mar;35(2):169-78.

Curriculum vitae


99. Eisen T, Sternberg CN, Robert C, Mulders P, Pyle L, Zbinden S, Izzedine H, Escudier B. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012 Jan 18;104(2):93-113. Epub 2012 Jan 10. Review. Erratum in: J Natl Cancer Inst. 2012 Apr 18;104(8):638.

100. Desar IM, ter Voert EG, Hambrock T, van Asten JJ, van Spronsen DJ, Mulders PF, Heerschap A, van der Graaf WT, van Laarhoven HW, van Herpen CM. Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging. 2012 Jan 12;11:259-65.

101. Dijkstra S, van der Heijden AG, Schaafsma HE, Mulders PF. Synchronous penile metastasis from a high-grade adenocarcinoma of the prostate. Case Rep Urol. 2012;2012:193787. Epub 2012 Oct 16.

102. Stillebroer AB, Zegers CM, Boerman OC, Oosterwijk E, Mulders PF, O'Donoghue JA, Visser EP, Oyen WJ. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J Nucl Med. 2012 Jan;53(1):82-9. Epub 2011 Dec 12.

103. Capitanio U, Becker F, Blute ML, Mulders P, Patard JJ, Russo P, Studer UE, Van Poppel H. Lymph node dissection in renal cell carcinoma. Eur Urol. 2011 Dec;60(6):1212-20. Epub 2011 Sep 13.

104. Robert G, Smit F, Hessels D, Jannink S, Karthaus HF, Aalders T, Jansen K, de la Taille A, Mulders PF, Schalken JA. Biomarkers for the diagnosis of prostatic inflammation in benign prostatic hyperplasia. Prostate. 2011 Nov;71(15):1701-9. Epub 2011 Mar 28.

105. Mulders P, Kirkali Z. Renal cell carcinoma: a changing paradigm with a need for consensus. Eur Urol. 2011 Oct;60(4):613-4. Epub 2011 Jul 13.

106. Margulis V, Master VA, Cost NG, Leibovich BC, Joniau S, Kuczyk M, Mulders PF, Kirkali Z, Wirth MP, Hirao Y, Rawal S, Chong TW, Wood CG. International consultation on urologic diseases and the European Association of Urology international consultation on locally advanced renal cell carcinoma. Eur Urol. 2011 Oct;60(4):673-83. Epub 2011 Jun 29.

107. Oosterwijk E, Rathmell WK, Junker K, Brannon AR, Pouliot F, Finley DS, Mulders PF, Kirkali Z, Uemura H, Belldegrun A. Basic research in kidney cancer. Eur Urol. 2011 Oct;60(4):622-33. Epub 2011 Jul 5. Review.

108. Patard JJ, Pignot G, Escudier B, Eisen T, Bex A, Sternberg C, Rini B, Roigas J, Choueiri T, Bukowski R, Motzer R, Kirkali Z, Mulders P, Bellmunt J. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011 Oct;60(4):684-90. Epub 2011 Jun 24.

109. Kats-Ugurlu G, Maass C, van Herpen C, de Waal R, Oosterwijk E, Mulders P, Hulsbergen-van de Kaa C, Leenders W. Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production. Histopathology. 2011 Sep;59(3):562-4.

110. Desar IM, Jacobs JH, Hulsbergen-vandeKaa CA, Oyen WJ, Mulders PF, van der Graaf WT, Adema GJ, van Herpen CM, de Vries IJ. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer. 2011 Jul 15;129(2):507-12. Epub 2010 Nov 12.

111. Mulder SF, Jacobs JF, Olde Nordkamp MA, Galama JM, Desar IM, Torensma R, Teerenstra S, Mulders PF, Vissers KC, Punt CJ, de Vries IJ, van Herpen CM. Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination. Clin Cancer Res. 2011 Jul 1;17(13):4541-9. Epub 2011 Jun 28.

112. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26;364(21):1995-2005.

Curriculum vitae


113. Bellmunt J, Eisen T, Szczylik C, Mulders P, Porta C. A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options. BJU Int. 2011 Apr;107(8):1190-9. Epub 2010 Nov 15.

114. Oosterwijk-Wakka JC, Kats-Ugurlu G, Leenders WP, Kiemeney LA, Old LJ, Mulders PF, Oosterwijk E. Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250. BJU Int. 2011 Jan;107(1): 118-25.

115. Langenhuijsen JF, van Lin EN, Hoffmann AL, Spitters-Post I, Alfred Witjes J, Kaanders JH, Mulders PF. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy. Urol Oncol. 2011 Jan-Feb;29(1):52-7. Epub 2009 Jun 12.

116. Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials. Eur Urol. 2010 Dec;58(6):819-28. Epub 2010 Aug 27.

117. Mulders PF, Abrahamsson PA, Bukowski RM. Burden of metastatic bone disease from genitourinary malignancies. Expert Rev Anticancer Ther. 2010 Nov;10(11):1721-33.

118. Desar IM, Stillebroer AB, Oosterwijk E, Leenders WP, van Herpen CM, van der Graaf WT, Boerman OC, Mulders PF, Oyen WJ. 111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. J Nucl Med. 2010 Nov;51(11):1707-15. Epub 2010 Oct 18.

119. Rossi JF, Négrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B. A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer. 2010 Oct 12;103(8):1154-62. Epub 2010 Aug 31.

120. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Bastien L, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, Van Gils MP, Schalken JA, de La Taille A. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int. 2010 Oct;106(8):1143-7.

121. Pfeiffer MJ, Mulders PF, Schalken JA. An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. Prostate. 2010 Oct 1;70(14):1524-32.

122. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC; European Association of Urology Guideline Group. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010 Sep;58(3):398-406. Epub 2010 Jul 12.

123. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol. 2010 Jul;58(1):75-83. Epub 2010 Mar 23. Review.

124. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1;362(13):1192-202.

125. Gore ME, Griffin CL, Hancock B, Patel PM, Pyle L, Aitchison M, James N, Oliver RT, Mardiak J, Hussain T, Sylvester R, Parmar MK, Royston P, Mulders PF. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet. 2010 Feb 20;375(9715):641-8. Epub 2010 Feb 10.

126. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 2010 Feb;36(1):16-23. Epub 2009 Oct 9.

Curriculum vitae


127. Mulders P. Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: differences and synergies of two targeted mechanisms. BJU Int. 2009 Dec;104(11):1585-9.

128. Jeldres C, Sun M, Liberman D, Lughezzani G, de la Taille A, Tostain J, Valeri A, Cindolo L, Ficarra V, Artibani W, Zigeuner R, Mejean A, Descotes JL, Lechevallier E, Mulders PF, Perrotte P, Patard JJ, Karakiewicz PI. Can renal mass biopsy assessment of tumor grade be safely substituted for by a predictive model? J Urol. 2009 Dec;182(6):2585-9.

129. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrun AS, Zini L, de la Taille A, Chautard D, Descotes JL, Shariat SF, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. J Urol. 2009 Dec;182(6):2607-12. Epub 2009 Oct 17.

130. Kats-Ugurlu G, Roodink I, de Weijert M, Tiemessen D, Maass C, Verrijp K, van der Laak J, de Waal R, Mulders P, Oosterwijk E, Leenders W. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear cell renal cell carcinoma. J Pathol. 2009 Nov;219(3):287-93.

131. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF, Schalken JA. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: a randomized, open-label, parallel-group pilot study. Prostate. 2009 Nov 1;69(15):1624-34.

132. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Stillebroer AB, van Gils MP, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Haese A. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009 Oct;56(4):659-67. Epub 2009 Mar 13.

133. Wood CG, Mulders P. Vitespen: a preclinical and clinical review. Future Oncol. 2009 Aug;5(6):763-74.

134. Mulders P. Editorial comment on: Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma. Eur Urol. 2009 Jul;56(1):132-3. Epub 2008 Jun 4.

135. Heesakkers RA, Jager GJ, Hövels AM, de Hoop B, van den Bosch HC, Raat F, Witjes JA, Mulders PF, van der Kaa CH, Barentsz JO. Prostate cancer: detection of lymph node metastases outside the routine surgical area with ferumoxtran-10-enhanced MR imaging. Radiology. 2009 May;251(2):408-14.

136. Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, de la Taille A, Tostain J, Mulders PF, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valéri A, Descotes JL, Rambeaud JJ, Méjean A, Montorsi F, Bertini R, Patard JJ. A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol. 2009 Feb;55(2):287-95. Epub 2008 Jul 25.

137. Wagner B, Patard JJ, Méjean A, Bensalah K, Verhoest G, Zigeuner R, Ficarra V, Tostain J, Mulders P, Chautard D, Descotes JL, de la Taille A, Salomon L, Prayer-Galetti T, Cindolo L, Valéri A, Meyer N, Jacqmin D, Lang H. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma. Eur Urol. 2009 Feb;55(2):452-9. Epub 2008 Aug 5.

138. Desar IM, Mulder SF, Stillebroer AB, van Spronsen DJ, van der Graaf WT, Mulders PF, van Herpen CM. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 2009;48(6):927-31.

139. Capitanio U, Jeldres C, Patard JJ, Perrotte P, Zini L, de La Taille A, Ficarra V, Cindolo L, Bensalah K, Artibani W, Tostain J, Valeri A, Zigeuner R, Méjean A, Descotes JL, Lechevallier E, Mulders PF, Lang H, Jacqmin D, Karakiewicz PI. Stage-specific effect of nodal metastases on survival in patients with non-metastatic renal cell carcinoma. BJU Int. 2009 Jan;103(1):33-7. Epub 2008 Oct 16.

140. Mulders PF. Editorial comment on: Ischemic renal damage after nephron-sparing surgery in patients with normal contralateral kidney. Eur Urol. 2009 Jan;55(1):215-6. Epub 2008 Aug 5.

Curriculum vitae


141. Mulders PF, Schalken JA. Measuring therapeutic efficacy in the changing paradigm of castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2009;12(3):241-6. Epub 2009 Jul 14.

142. Karakiewicz PI, Jeldres C, Suardi N, Hutterer GC, Perrotte P, Capitanio U, Ficarra V, Cindolo L, de La Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Schips L, Chautard D, Valeri A, Lechevallier E, Descots JL, Lang H, Mejean A, Verhoest G, Patard JJ. Age at diagnosis is a determinant factor of renal cell carcinoma-specific survival in patients treated with nephrectomy. Can Urol Assoc J. 2008 Dec;2(6):610-7.

143. Heesakkers JP, Mulders PF. [The practice guideline 'Urinary incontinence' (first revision) from the Dutch College of General Practitioners; a response from the perspective of urology]. Ned Tijdschr Geneeskd. 2008 Nov 22;152(47):2544-5. Dutch.

144. d'Ancona FC, Mulders PF. [The practice guideline 'Urolithiasis' (first revision) from the Dutch College of General Practitioners; a response from the perspective of urology]. Ned Tijdschr Geneeskd. 2008 Nov 8;152(45):2442. Dutch. PubMed PMID: 19051793.

145. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S, Stillebroer AB, van Gils MP, Schalken JA. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008 Nov;54(5):1081-8. Epub 2008 Jun 26.

146. Aben KK, Luth TK, Janssen-Heijnen ML, Mulders PF, Kiemeney LA, van Spronsen DJ. No improvement in renal cell carcinoma survival: a population-based study in the Netherlands. Eur J Cancer. 2008 Aug;44(12):1701-9. Epub 2008 May 22.

147. Brouwers AH, Mulders PF, Oyen WJ. Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. J Clin Oncol. 2008 Aug 1;26(22):3808-9; author reply 3811-2.

148. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008 Aug 1;68(11):1215-22.

149. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, Gupta R, Escudier B; C-100-12 RCC Study Group. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet. 2008 Jul 12;372(9633):145-54. Epub 2008 Jul 3.

150. Mommers E, Kersemaekers WM, Elliesen J, Kepers M, Apter D, Behre HM, Beynon J, Bouloux PM, Costantino A, Gerbershagen HP, Grønlund L, Heger-Mahn D, Huhtaniemi I, Koldewijn EL, Lange C, Lindenberg S, Meriggiola MC, Meuleman E, Mulders PF, Nieschlag E, Perheentupa A, Solomon A, Väisälä L, Wu FC, Zitzmann M. Male hormonal contraception: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2008 Jul;93(7):2572-80. Epub 2008 Apr 15.

151. Thorgeirsson TE, Geller F, Sulem P, Rafnar T, Wiste A, Magnusson KP, Manolescu A, Thorleifsson G, Stefansson H, Ingason A, Stacey SN, Bergthorsson JT, Thorlacius S, Gudmundsson J, Jonsson T, Jakobsdottir M, Saemundsdottir J, Olafsdottir O, Gudmundsson LJ, Bjornsdottir G, Kristjansson K, Skuladottir H, Isaksson HJ, Gudbjartsson T, Jones GT, Mueller T, Gottsäter A, Flex A, Aben KKH, de Vegt F, Mulders PFA, Isla D, Vidal MJ, Asin L, Saez B, Murillo L, Blondal T, Kolbeinsson H, Stefansson JG, Hansdottir I, Runarsdottir V, Pola R, Lindblad B, van Rij AM, Dieplinger B, Haltmayer M, Mayordomo JI, Kiemeney LA, Matthiasson SE, Oskarsson H, Tyrfingsson T, Gudbjartsson DF, Gulcher JR, Jonsson S, Thorsteinsdottir U, Kong A, Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature. 2008 Apr 3;452(7187):638-642.

152. Mulders PF. Renal cell carcinoma. World J Urol. 2008 Apr;26(2):113. Epub 2008 Apr 4.

Curriculum vitae


153. Oosterwijk E, Boerman OC, Oyen WJ, Old LJ, Mulders PF. Antibody therapy in renal cell carcinoma. World J Urol. 2008 Apr;26(2):141-6. Epub 2008 Feb 1. Review.

154. Mulders PF, Brouwers AH, Hulsbergen-van der Kaa CA, van Lin EN, Osanto S, de Mulder PH. [Guideline 'Renal cell carcinoma']. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):376-80.

155. de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJ, Osanto S, Jansen RL, Mulders PF. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. Ned Tijdschr Geneeskd. 2008 Feb 16;152(7):371-5.

156. Hutterer GC, Patard JJ, Jeldres C, Perrotte P, de La Taille A, Salomon L, Verhoest G, Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Karakiewicz PI. Patients with distant metastases from renal cell carcinoma can be accurately identified: external validation of a new nomogram. BJU Int. 2008 Jan;101(1):39-43. Epub 2007 Oct 1.

157. Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T. Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(1):46-52. Epub 2007 Jul 3.

158. Hutterer GC, Patard JJ, Perrotte P, Ionescu C, de La Taille A, Salomon L, Verhoest G, Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Valeri A, Chautard D, Descotes JL, Rambeaud JJ, Mejean A, Karakiewicz PI. Patients with renal cell carcinoma nodal metastases can be accurately identified: external validation of a new nomogram. Int J Cancer. 2007 Dec 1;121(11):2556-61.

159. Stillebroer AB, Oosterwijk E, Oyen WJ, Mulders PF, Boerman OC. Radiolabeled antibodies in renal cell carcinoma. Cancer Imaging. 2007 Nov 19;7:179-88.

160. Karakiewicz PI, Hutterer GC, Trinh QD, Pantuck AJ, Klatte T, Lam JS, Guille F, de La Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Schips L, Zigeuner R, Mulders PF, Chautard D, Lechevallier E, Valeri A, Descotes JL, Lang H, Soulie M, Ferriere JM, Pfister C, Mejean A, Belldegrun AS, Patard JJ. Unclassified renal cell carcinoma: an analysis of 85 cases. BJU Int. 2007 Oct;100(4):802-8.

161. Karakiewicz PI, Trinh QD, Rioux-Leclercq N, de la Taille A, Novara G, Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R, Mulders PF, Lechevallier E, Coulange C, Valeri A, Descotes JL, Rambeaud JJ, Abbou CC, Lang H, Jacqmin D, Mejean A, Patard JJ. Collecting duct renal cell carcinoma: a matched analysis of 41 cases. Eur Urol. 2007 Oct;52(4):1140-5. Epub 2007 Jan 31.

162. Ficarra V, Galfano A, Guillé F, Schips L, Tostain J, Mejean A, Lang H, Mulders P, De La Taille A, Chautard D, Descotes JL, Cindolo L, Novara G, Rioux-Leclercq N, Zattoni F, Artibani W, Patard JJ. A new staging system for locally advanced (pT3-4) renal cell carcinoma: a multicenter European study including 2,000 patients. J Urol. 2007 Aug;178(2):418-24; discussion 423-4. Epub 2007 Jun 11.

163. Ljungberg B, Hanbury DC, Kuczyk MA, Merseburger AS, Mulders PF, Patard JJ, Sinescu IC; European Association of Urology Guideline Group for renal cell carcinoma. Renal cell carcinoma guideline. Eur Urol. 2007 Jun;51(6):1502-10. Epub 2007 Mar 28.

164. Karakiewicz PI, Trinh QD, Bhojani N, Bensalah K, Salomon L, de la Taille A, Tostain J, Cindolo L, Altieri V, Ficarra V, Schips L, Zigeuner R, Mulders PF, Valeri A, Descotes JL, Mejean A, Patard JJ. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: prognostic indicators of disease-specific survival. Eur Urol. 2007 Jun;51(6):1616-24. Epub 2006 Dec 14.

165. van Gils MP, Cornel EB, Hessels D, Peelen WP, Witjes JA, Mulders PF, Rittenhouse HG, Schalken JA. Molecular PCA3 diagnostics on prostatic fluid. Prostate. 2007 Jun 1;67(8):881-7.

166. Verhoest G, Veillard D, Guillé F, De La Taille A, Salomon L, Abbou CC, Valéri A, Lechevallier E, Descotes JL, Lang H, Jacqmin D, Tostain J, Cindolo L, Ficarra V, Artibani W, Schips L, Zigeuner R,

Curriculum vitae


Mulders PF, Mejean A, Patard JJ. Relationship between age at diagnosis and clinicopathologic features of renal cell carcinoma. Eur Urol. 2007 May;51(5):1298-304; discussion 1304-5. Epub 2006 Dec 8.

167. Karakiewicz PI, Briganti A, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. J Clin Oncol. 2007 Apr 10;25(11):1316-22.

168. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007 Feb 1;13(3):939-43.

169. Bleumer I, Tiemessen DM, Oosterwijk-Wakka JC, Völler MC, De Weijer K, Mulders PF, Oosterwijk E. Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells. J Immunother. 2007 Jan;30(1):116-22.

170. Jiang X, Holsheimer J, Wagner G, Mulders P, Meuleman E. A reproducibility study of corpus cavernosum electromyography in young healthy volunteers under controlled conditions. J Sex Med. 2007 Jan;4(1):183-90. Epub 2006 Nov 1. Erratum in: J Sex Med. 2007 Mar;4(2):522. Wijkstra, Hessel [removed]. PubMed PMID: 17081218.

171. Oosterwijk E, Mulders PF. The importance of cyclooxygenase in carcinogenesis: is it a therapeutic target? Eur Urol. 2006 Jul;50(1):23-5. Epub 2006 Jan 19.

172. Baumert H, Ballaro A, Arroyo C, Kaisary AV, Mulders PF, Knipscheer BC. The use of polymer (Hem-o-lok) clips for management of the renal hilum during laparoscopic nephrectomy. Eur Urol. 2006 May;49(5):816-9. Epub 2006 Feb 24.

173. Bleumer I, de Mulder PH, Mulders PF. The role of adjuvant therapy in non-metastatic RCC. Can J Urol. 2006 Apr;13 Suppl 2:57-62. Review.

174. Kuijpers KA, Mulders PF. [The practice guideline 'Urinary-tract infections' (second revision) from the Dutch College of General Practitioners; a response from the perspective of urology]. Ned Tijdschr Geneeskd. 2006 Apr 1;150(13):715-7. Dutch.

175. Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF. A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma. J Urol. 2006 Jan;175(1):57-62.

176. van Gils MP, Stenman UH, Schalken JA, Schröder FH, Luider TM, Lilja H, Bjartell A, Hamdy FC, Pettersson KS, Bischoff R, Takalo H, Nilsson O, Mulders PF, Bangma CH. Innovations in serum and urine markers in prostate cancer current European research in the P-Mark project. Eur Urol. 2005 Dec;48(6):1031-41. Epub 2005 Jul 1. Review.

177. Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s.

178. Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J Clin Oncol. 2005 Sep 20;23(27):6540-8. PubMed PMID: 16170161.

179. van Spronsen DJ, Mulders PF, De Mulder PH. Novel treatments for metastatic renal cell carcinoma. Crit Rev Oncol Hematol. 2005 Sep;55(3):177-91.

Curriculum vitae


180. Jongmans W, Tiemessen DM, van Vlodrop IJ, Mulders PF, Oosterwijk E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother. 2005 Sep-Oct;28(5):480-7.

181. van Spronsen DJ, de Weijer KJ, Mulders PF, De Mulder PH. Novel treatment strategies in clear-cell metastatic renal cell carcinoma. Anticancer Drugs. 2005 Aug;16(7):709-17. Review.

182. van Gils MP, Mulders PF. [The practice guideline 'Lower urinary-tract symptoms in middle-aged and elderly men' (second revision) from the Dutch College of General Practitioners; a response from the perspective of urology]. Ned Tijdschr Geneeskd. 2005 Jul 9;149(28):1551-2. Dutch.

183. Aass N, De Mulder PH, Mickisch GH, Mulders P, van Oosterom AT, van Poppel H, Fossa SD, de Prijck L, Sylvester RJ. Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951). J Clin Oncol. 2005 Jun 20;23(18):4172-8.

184. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guillé F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005 Apr 20;23(12):2763-71.

185. Deserno WM, Harisinghani MG, Taupitz M, Jager GJ, Witjes JA, Mulders PF, Hulsbergen van de Kaa CA, Kaufmann D, Barentsz JO. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology. 2004 Nov;233(2):449-56. Epub 2004 Sep 16.

186. Mulders P, Bleumer I, Debruyne F, Oosterwijk E. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX(G250/MN). Urologe A. 2004 Sep;43 Suppl 3:S146-7.

187. Patard JJ, Kim HL, Lam JS, Dorey FJ, Pantuck AJ, Zisman A, Ficarra V, Han KR, Cindolo L, De La Taille A, Tostain J, Artibani W, Dinney CP, Wood CG, Swanson DA, Abbou CC, Lobel B, Mulders PF, Chopin DK, Figlin RA, Belldegrun AS. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol. 2004 Aug 15;22(16):3316-22.

188. Brouwers A, Mulders P, Oosterwijk E, Buijs W, Corstens F, Boerman O, Oyen W. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. Cancer Biother Radiopharm. 2004 Aug;19(4):466-77.

189. Patard JJ, Shvarts O, Lam JS, Pantuck AJ, Kim HL, Ficarra V, Cindolo L, Han KR, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Chopin DK, Figlin RA, Mulders PF, Belldegrun AS. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol. 2004 Jun;171(6 Pt 1):2181-5, quiz 2435.

190. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer. 2004 Mar 8;90(5):985-90.

191. Steffens MG, de Mulder PH, Mulders PF. [Paraneoplastic syndromes in three patients with renal cell carcinoma]. Ned Tijdschr Geneeskd. 2004 Mar 6;148(10):487-92.

192. Han KR, Bleumer I, Pantuck AJ, Kim HL, Dorey FJ, Janzen NK, Zisman A, Dinney CP, Wood CG, Swanson DA, Said JW, Figlin RA, Mulders PF, Belldegrun AS. Validation of an integrated staging system toward improved prognostication of patients with localized renal cell carcinoma in an international population. J Urol. 2003 Dec;170(6 Pt 1):2221-4.

193. Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody

Curriculum vitae


G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S.

194. Gitlitz BJ, Belldegrun AS, Zisman A, Chao DH, Pantuck AJ, Hinkel A, Mulders P, Moldawer N, Tso CL, Figlin RA. A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J Immunother. 2003 Sep-Oct;26(5):412-9.

195. Jongmans W, van den Oudenalder K, Tiemessen DM, Molkenboer J, Willemsen R, Mulders PF, Oosterwijk E. Targeting of adenovirus to human renal cell carcinoma cells. Urology. 2003 Sep;62(3):559-65.

196. Oosterwijk E, Divgi CR, Brouwers A, Boerman OC, Larson SM, Mulders P, Old LJ. Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am. 2003 Aug;30(3):623-31.

197. Mulders P, Bleumer I, Oosterwijk E. Tumor antigens and markers in renal cell carcinoma. Urol Clin North Am. 2003 Aug;30(3):455-65. Review.

198. Bleumer I, Oosterwijk E, De Mulder P, Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol. 2003 Jul;44(1):65-75.

199. Jongmans W, Tiemessen DM, Oosterwijk E, Mulders PF. Correspondence re: Y. S. Haviv, J. L. Blackwell, A. Kanerva, P. Nagi, V. Krasnykh, I. Dmitriev, M. Wang, S. Naito, X. Lei, A. Hemminki, D. Carey, and D. T. Curiel, Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res., 62: 4273-4281, 2002. Cancer Res. 2003 Apr 15;63(8):1994-5.

200. Meuleman EJ, Mulders PF. Erectile function after radical prostatectomy: a review. Eur Urol. 2003 Feb;43(2):95-101; discussion 101-2. Review.

201. Oosterwijk E, Brouwers A, Boerman OC, Larson SM, Old LJ, Mulders P, Divgi CR. Monoclonal antibody therapy of kidney cancer. Cancer Treat Res. 2003;116:199-212. Review.

202. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, Scheibenbogen C, Uiters J, Wanders J, Delire M, Boon T, Stoter G. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer. 2003 Jan;39(1):70-7.

203. Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P. A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients. Folia Biol (Praha). 2003;49(2):74-7.

204. van Erp F, Van Ravenswaaij C, Bodmer D, Eleveld M, Hoogerbrugge N, Mulders P, Geurts van Kessel A. Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. Genet Couns. 2003;14(2):149-54. Review.

205. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I, de Vries IJ, Jongmans W, Adema GJ, Debruyne FM, de Mulder PH, Oosterwijk E, Mulders PF. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study. J Immunother. 2002 Nov-Dec;25(6):500-8.

206. Steffens MG, Mulders PF, Brouwers AH, Oyen WJ. Re: Clinical role of f-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol. 2002 Nov;168(5):2127-8.

207. Mulders PF, De Mulder PH. The role of adjuvant immunotherapy in renal cell carcinoma. Curr Urol Rep. 2002 Feb;3(1):44-9. Review.

208. Mulders PF. Treatment strategies in metastatic renal cell carcinoma : cytokines, vaccines, and gene therapy. Methods Mol Med. 2001;53:343-59.

209. Mulders PF. Treatment of prostate cancer-use of specific monoclonal antibodies. Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S31.

Curriculum vitae


210. Van Poppel H, Nilsson S, Algaba F, Bergerheim U, Dal Cin P, Fleming S, Hellsten S, Kirkali Z, Klotz L, Lindblad P, Ljungberg B, Mulders P, Roskams T, Ross RK, Walker C, Wersäll P. Precancerous lesions in the kidney. Scand J Urol Nephrol Suppl. 2000;(205):136-65.

211. Punt CJ, de Vries IJ, Mulders PF, Adema GJ, Figdor CG. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer]. Ned Tijdschr Geneeskd. 1999 Nov 27;143(48):2408-14.

212. van Kessel AG, Wijnhoven H, Bodmer D, Eleveld M, Kiemeney L, Mulders P, Weterman M, Ligtenberg M, Smeets D, Smits A. Renal cell cancer: chromosome 3 translocations as risk factors. J Natl Cancer Inst. 1999 Jul 7;91(13):1159-60.

213. Mulders P, Tso CL, Gitlitz B, Kaboo R, Hinkel A, Frand S, Kiertscher S, Roth MD, deKernion J, Figlin R, Belldegrun A. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin Cancer Res. 1999 Feb;5(2):445-54.

214. Mulders PF. Treatment of advanced prostate cancer: the vaccine approach. Scand J Urol Nephrol Suppl. 1999;203:41-3.

215. Mulders P, Tso CL, Pang S, Kaboo R, McBride WH, Hinkel A, Gitlitz B, Dannull J, Figlin R, Belldegrun A. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother. 1998 May;21(3):170-80.

216. Mulders P, Pang S, Dannull J, Kaboo R, Hinkel A, Michel K, Tso CL, Roth M, Belldegrun A. Highly efficient and consistent gene transfer into dendritic cells utilizing a combination of ultraviolet-irradiated adenovirus and poly(L-lysine) conjugates. Cancer Res. 1998 Mar 1;58(5):956-61.

217. Mulders PF. Re: Bilateral ureteral obstruction after asymptomatic appendicitis. J Urol. 1998 Feb;159(2):512.

218. Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D, deWolf W, Belldegrun A. Renal cell carcinoma: recent progress and future directions. Cancer Res. 1997 Nov 15;57(22):5189-95.

219. Hugen CA, Mulders PF, Monnens LA, Dijkman-Neerincx RH, de Vries JD. Bilateral ureteral obstruction after appendectomy in children. J Pediatr Surg. 1995 Dec;30(12):1666-7.

220. Steyerberg EW, Keizer HJ, Fosså SD, Sleijfer DT, Toner GC, Schraffordt Koops H, Mulders PF, Messemer JE, Ney K, Donohue JP, et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study groups. J Clin Oncol. 1995 May;13(5):1177-87.

221. Hugen CA, Mulders PF, Monnens LA, de Vries JD. Complete bilateral distal ureteral obstruction after appendicectomy. Lancet. 1994 Aug 27;344(8922):618-9.

222. van der Poel HG, Mulders PF, Aalders TW, Oosterhof GO, Debruyne FM, Schalken JA. Karyometric analysis of intra-tumour heterogeneity in prostate adenocarcinoma. Anal Cell Pathol. 1994 Aug;7(2):153-70.

223. Mulders PF, Meyden AP, Doesburg WH, Oosterhof GO, Debruyne FM. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group. Br J Urol. 1994 Apr;73(4):403-8.

224. Witjes JA, Mulders PF, Debruyne FM. Intravesical therapy in superficial bladder cancer. Urology. 1994 Feb;43(2 Suppl):2-5; discussion 6. PubMed PMID: 8116130.

225. Mulders PF, Hoekstra WJ, Heybroek RP, Schapers ER, Verbeek AL, Oosterhof GO, Debruyne FM. Prognosis and treatment of T1G3 bladder tumours. A prognostic factor analysis of 121 patients. Dutch South Eastern Bladder Cancer Study Group. Eur J Cancer. 1994;30A(7):914-7.

Curriculum vitae


226. van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. Tumor heterogeneity as prognostic factor in patients with low-stage (T1-3N0M0) renal-cell carcinoma. Investig Urol (Berl). 1994;5:60-5.

227. van der Poel HG, Mulders PF, Oosterhof GO, Schaafsma HE, Hendriks JC, Schalken JA, Debruyne FM. Prognostic value of karyometric and clinical characteristics in renal cell carcinoma. Quantitative assessment of tumor heterogeneity. Cancer. 1993 Nov 1;72(9):2667-74.

228. Mulders PF, Fernandez del Moral P, Theeuwes AG, Oosterhof GO, van Berkel HT, Debruyne FM. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol. 1992;21(1):2-5.

229. Mulders PF, Oosterhof GO, Boetes C, de Mulder PH, Theeuwes AG, Debruyne FM. The importance of prognostic factors in the individual treatment of patients with disseminated germ cell tumours. Br J Urol. 1990 Oct;66(4):425-9.

230. Mulders PF, Dijkman GA, Fernandez del Moral P, Theeuwes AG, Debruyne FM. Analysis of prognostic factors in disseminated prostatic cancer. An update. Dutch Southeastern Urological Cooperative Group. Cancer. 1990 Jun 15;65(12):2758-61.

231. Mulders PF, Debruyne FM. [The prognostic significance of alkaline and acid phosphatase levels in the hormonal treatment of patients with prostatic carcinoma]. Ned Tijdschr Geneeskd. 1987 Aug 8;131(32):1399-402.

Abstracts 1. Improved survival in elderly (> 75 yr) metastatic castration-resistant prostate cancer (mCRPC)

patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phse III study. P.F.A. Mulders, A. Molina, M. Marberger, F. Saad,. J.H. Li, T. Kheoh, C.M. Haqq, K. Fizazi. 27th EAU Annual Congress, Paris, 2012.

2. Combination of Sunitinib and mAB cG250 in nude mice bearing human renal cell carcinoma xenografts. J.C. Oosterwijk-Wakka, P.F.A. Mulders, E. Oosterwijk. 27th EAU Annual Congress, Paris, 2012.

3. Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort. M. Auprich, A. Haese, A. De la Taille, H. Van Poppel, M. Marberger, P.F.A. Mulders, C.C. Abbou, A.B. Stillebroer, M.P.M.Q. van Gils, J.A. Schalken, A. Stenzl, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, J. Walz, F.K.H. Chun. 27

th EAU

Annual Congress, Paris, 2012. 4. Transcriptome analysis of renal cell carcinoma and normal kidney tissue for the identification of

new diagnostic and prognostic biomarkers. K. Nagao, F. Smit, M.C.A. De Weijert, S. Jannink, J.A. Schalken, P.F.A. Mulders, E. Oosterwijk. 27th EAU Annual Congress, Paris, 2012.

5. Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate. F.K. Chun, J. Hansen, A. De la Taille, H. Van Poppel, M. Marberger, A. Stenzl, P.F.A. Mulders, H. Huland, C.C. Abbou, A.B. Stillebroer, M.P.M.Q. van Gils, J.A. Schalken, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, A. Haese, K. Pummer, M. Auprich. 27th EAU Annual Congress, Paris, 2012.

6. Prospective multicenter evaluation of PCA3+TMPRSS2-ERG as a diagnostic and prognostic marker panel for prostate cancer. G.H.J.M. Leyten, D. Hessels, E.B. Cornel, T.M. De Reijke, H. Vergunst, P. Kil, B.C. Knipscheer, I.M. Van Oort, P.F.A. Mulders. 27th EAU Annual Congress, Paris, 2012.

7. Targeting CAIX: Indium-111 labeled cG250 as a diagnostic tool for renal masses and lesions suspected for metastasis of clear cell carcinoma. C.H.J. Muselaers, E. Oosterwijk, O.C. Boerman, W.J.G. Oyen, P.F.A. Mulders. 27th EAU Annual Congress, Paris, 2012.

Curriculum vitae


8. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Karim Fizazi, Howard I. Scher, Fred Saad, Cora N. Sternberg, Kurt Miller, Peter Mulders, Kim N. Chi, Ethan M. Basch, Mohammad Hirmand, Johan S. de Bono. ESMO 2012.

9. Improved survival in elderly (> 75 yr) metastatic castration-resistant prostate cancer (mCRPC) patients upon treatment with abiraterone acetate (AA) plus prednisone (P) progressing after docetaxel-based chemotherapy: Results from COU-AA-301, a randomized, double-blind, placebo-controlled, phse III study. P.F.A. Mulders, A. Molina, M. Marberger, F. Saad,. J.H. Li, T. Kheoh, C.M. Haqq, K. Fizazi. 27th EAU Annual Congress, Paris, 2012.

10. Combination of Sunitinib and mAB cG250 in nude mice bearing human renal cell carcinoma xenografts. J.C. Oosterwijk-Wakka, P.F.A. Mulders, E. Oosterwijk. 27th EAU Annual Congress, Paris, 2012.

11. Development of novel PCA3 cut-offs for initial and repeat biopsy using different statistical approaches within a US-European multi institutional cohort. M. Auprich, A. Haese, A. De la Taille, H. Van Poppel, M. Marberger, P.F.A. Mulders, C.C. Abbou, A.B. Stillebroer, M.P.M.Q. van Gils, J.A. Schalken, A. Stenzl, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, J. Walz, F.K.H. Chun. 27th EAU Annual Congress, Paris, 2012.

12. Transcriptome analysis of renal cell carcinoma and normal kidney tissue for the identification of new diagnostic and prognostic biomarkers. K. Nagao, F. Smit, M.C.A. De Weijert, S. Jannink, J.A. Schalken, P.F.A. Mulders, E. Oosterwijk. 27

th EAU Annual Congress, Paris, 2012.

13. Biopsy-specific PCA3-based prostate biopsy nomograms are highly accurate. F.K. Chun, J. Hansen, A. De la Taille, H. Van Poppel, M. Marberger, A. Stenzl, P.F.A. Mulders, H. Huland, C.C. Abbou, A.B. Stillebroer, M.P.M.Q. van Gils, J.A. Schalken, Y. Fradet, L.S. Marks, W. Ellis, A.W. Partin, A. Haese, K. Pummer, M. Auprich. 27th EAU Annual Congress, Paris, 2012.

14. Prospective multicenter evaluation of PCA3+TMPRSS2-ERG as a diagnostic and prognostic marker panel for prostate cancer. G.H.J.M. Leyten, D. Hessels, E.B. Cornel, T.M. De Reijke, H. Vergunst, P. Kil, B.C. Knipscheer, I.M. Van Oort, P.F.A. Mulders. 27th EAU Annual Congress, Paris, 2012.

15. Targeting CAIX: Indium-111 labeled cG250 as a diagnostic tool for renal masses and lesions suspected for metastasis of clear cell carcinoma. C.H.J. Muselaers, E. Oosterwijk, O.C. Boerman, W.J.G. Oyen, P.F.A. Mulders. 27

th EAU Annual Congress, Paris, 2012.

16. Impact of enzalutamide, an androgen receptor signaling inhibitor, on time to first skeletal related event (SRE) and pain in the phase 3 AFFIRM study. Karim Fizazi, Howard I. Scher, Fred Saad, Cora N. Sternberg, Kurt Miller, Peter Mulders, Kim N. Chi, Ethan M. Basch, Mohammad Hirmand, Johan S. de Bono. ESMO 2012.

17. Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib Decreases 111Indium-Girentuximab Uptake in Clear Cell Renal Cell Carcinoma Patients. Peter F.A. Mulders, Constantijn H.J. Muselaers, Mirjam C.A. de Weijert, Otto C. Boerman, Wim J.G. Oyen, Egbert Oosterwijk. 28th meeting of the Urological Research Society, Osaka, October 4-7, 2012.

18. Enzalutamide, an androgen receptor signaling inhibitor, improves overall survival, time to first skeletal related event and pain. P. Mulders, K. Fizazi, F. Saad, C.N. Sterberg, M. Taplin, A. Heidenreich, M. Hirmand, A.J. Armstrong, E.M. Basch. 4th Eurpean Multidisciplinary Meeting on Urological Cancers (EMUC), Barcelona, November 16-18, 2012.

19. The role of radio-immunotherapy in the targeted therapy era in renal cell carcinoma patients. 11th Meeting of the Association of Academic European Urologists (AAEU), Salzburg, December 7-9, 2012.

Curriculum vitae


20. The impact of abiraterone acetate therapy on patient-reported pain and functional status in chemotherapy-naïve patients with progressive, metastatic castration-resistant prostate cancer – results from an updated analysis. Annual EAU Congress, Milan, March 15-19, 2013.

21. Abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy – Interim analysis of the COU-AA-302 phase 3 trial. AUA Annual Congress, San Diego, May 4-8, 2013.

22. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCROC): Results from COU-AA-302. Charles J. Ryan, Anil Londhe, Arturo Molina, Matthew R. Smith, Johann Sebastian De Bono, Peter Mulders, Dana E. Rathkopf, Fred Saad, Christopher Logothetis, Karim Fizazi, Howard I. Scher, Eric Jay Small, Shannon Matheny, Thian San Kheoh, Thomas W. Griffin. Annual meeting ASCO, Chicago, May 31-June 4, 2013.

23. Short term Tysosine kinase inhibition of renal cell carcinoma induces release of circulating tumor fragments. Peter Mulders, Egbert Oosterwijk, Stijn Muselaers, William Leenders. Annual meeting of the URS, Vancouver, December 4-7, 2013.

24. Prognostic index for progression-free survival in metastic castration-resistant prostate cancer patients without previous chemotherapy: an analysis of the COU-AA-302 abiraterone acetate study. Charles J. Ryan, Thian Kheoh, Arturo Molina, Joan Carles, Eleni Efsthathiou, Philip W. Kantoff, Peter F.A. Mulders, Fred Saad, Tom Griffin, Kim N. Chi. ESMO 2013.

25. Efficacy and safety of abiraterone acetate (AA) in elderly (> 75 years) chemo-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Matthew R. Smith, Dana Rathkopf, Peter Mulders, Joan Carles, Hendrik Van Poppel, Jinhui Li, Thian Kheoh, Thomas Griffin, Arturo Molina, Charles Ryan. ECCO-ESMO 2013.

26. Post hoc analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) in study COU-AA-302: response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA). Annual meeting of the EAU, Stockholm, April 11-15, 2014.

27. Preliminary data from P11-1, a phase 2, open-label trial of sipuleucel-T in European men with metastatic castrate-resistant prostate cancer (mCRPC). Peter Mulders, Maria De Santis, Karim Fizazi, James Whitmore, Nadeem Sheikh, Candice McCoy, Andy Stubbs and Thomas Powles. Annual meeting of the EAU, Stockholm, April 11-15, 2014.

28. Impact of prior endocrine therapy on clinical benefit of abiraterone acetate in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: result from COUI-AA-302. Fred Saad, Thian Kheoh, Margaret K. Yui, Matthew R. Smith, Eric J. Small, Peter F.A. Mulders, Karim Fizazi, Dana Rathkopf, Stéphane Oudard, Howard I. Scher, Joaquim Bellmunt, Mary-Ellen Taplin, Ian D. Davis, Dirk Schrijvers, Andrew Protheroe, Arturo Molina, Thomas W. Griffin, Johann S. de Bono, Charles J. Ryan. Annual meeting of the AUA, Orlando, May 16-21, 2014.

Books 1. Vaccines and other approaches in RCC. Oosterwijk E, Mulders PF. International Oncology Updates:

Recent advances in renal cell carcinoma (RCC). 2008 2. Tumor Targets and Biomarkers in renall cell carcinoma. The Bleumer, I, Mulders PF. Oncogenomics

Handbook, edited by William J. La Rochelle and Richard A. Shimkets, Humana Press Inc, 2005, p 89-104

3. Bloed in de urine, blaaskanker, nierkanker. Prins A, Bosch JL, Mulders PF. Praktische Huisartsengeneeskunde Urologie. Bohn Stafleu Van Loghum, Houten 2004, p192-197.

Curriculum vitae


4. Bosch RL, Kirkels WJ, Mickisch GH, Mulders PF, Schröder FH. Hematurie, p31-43, Urologie, redactie Bangma CH, Quintessens, 2002.

5. Monoclonal antibody therapy of kidney cancer. Oosterwijk E, Brouwers A, Boerman OC, Larson SM, Old LJ, Mulders PF, Divgi CR. P212-215, Kidney Cancer, 2002.

6. Treatment strategies in metastatic renal cell carcinoma, cytokines, vaccines and gene therapy. Mulders PF. P343-329. Renal Cancer, methods and protocols. Ed J. Mydlo, Humana Press Incolk Totowa, NJ, vol 53: 2001.

7. Renal and adrenal tumors: biology and management. Mulders PF. Tumor Markers. P34-47. Eds: Ritchie et al. Oxford University Press, Oxford, 2000.

8. Dendrictic cell immunotherapy in prostate cancer. Mulders PF. P21-37. New Perspectives in Prostate Cancer, 2nd ed, Isis Medical Ltd, Oxford, UK, 1999.

Book chapter Carbonic Anhydrase IX: Its role as a biomarker, diagnostic, and therapeutic target in renal cell carcinoma. Boek: Renal Cell Carcinoma. Translational Biology, Personalized Medicine, and Novel Therapeutic Targets (chapter 12). Onderzoeks projecten (principal investigator) KWF-053340 VEGF-induced micro nodular transformation and tumor embolism as an efficient

mechanism of metastatis: is tissue the issue? KWF-053339 Radio immunotherapy of cancer with Lu-177 labeled monoclonal antibodies and

bispecific antibodies. KWF-991827 Optimizing dendritic cell-based tumor immunization in renal cell carcinoma KWF-991973 Radio immunotherapy of renal cell carcinoma with chimeric monoclonal antibody

G250 KWF-022322 A clinical study on the role of an allergenic immune response boosted with dendritic

cells in the treatment of solid tumors Onderwijs

Opleider co-assistenten Heelkunde/Urologie

Plaatsvervangend opleider arts-assistenten Urologie

Docent Keuzeblok B202 : Tumorimmunologie

Docent Keuzeblok B202 : Genetische en Immunologische Processen

Docent Keuzeblok KMP7 : Gen- en Immunotherapie

Docent Keuzeblok 02-143 : Blok CAPITA-colleges, thema Voortplanting van Biomedische Wetenschappen

Mentor Medische student MaBa (Bachelor Master), UMC St Radboud Promotor

11-05-2004 dr. A.H. Brouwers Titel proefschrift Radioimmunotargeting of renal cell cancer using monoclonal antibody G250

27-06-2006 dr. I. Bleumer Titel proefschrift Specific immunotherapy for renal cell carcinoma

08-09-2009 dr. M.P.M.Q. van Gils Titel proefschrift Molecular diagnosis in prostate cancer. PCA3

02-07-2010 dr. D. Hessels

Curriculum vitae


Titel proefschrift PCA3 and prostate cancer diagnosis and prognosis

14-10-11 F.M.J. Martens Titel proefschrift Diagnosis of neurogenic detrusor overactivity and treatment with conditional electrical stimulation of the dorsal genital nerves

09-03-2012 J.F. Ferdinand Developments in prostate cancer treatment. Improving complication rates

09-05-2012 M.J. Pfeiffer Titel proefschrift Stem cells and steroid metabolism in prostate cancer

07-02-2014 A.B. Stilleboer Titel Radioimmunodiagnosis and - Therapy of renal cell carcinoma using the monoclonal antibody cG250

08-12-14 G.H.J.M. Leyten Titel Prognostic biomarkers for prostate cancer

22-05-2015 drs. C.H.J. Muselaers Titel proefschrift: Targeting renal cell carcinoma with radiolabled antibodies

09-12-2016 dr. J.C. Oosterwijk-Wakka Titel Improving treatment in Renal Cell Carcinoma with monoclonal antibody cG250

25-08-2017 drs. H.M.K. van Breda Titel: Overactive bladder in clinical practice and future neuromodulation treatments

Corona

R. ten Broek Promotion 31-10-2014 The burden of adhesions

Co-promoter Corona

A. van Bokhoven Promotion March 2004 Models for prostate cancer. Molecular characterization and critical appraisal of humane prostate carcinoma cell lines

Co-promoter

A. Brouwer Promotion January 2004 Radio immunotherapy in renal cell carcinoma

I. Bleumer Promotion April 2004 From a non-specific to specific immunotherapy in renal cell carcinoma

M. Lampe Promotion December 2004 Monoclonal antibodies in prostate cancer

X. Jiang Promotion June 2006 Corpus Cavernosum Electromyography in the Diagnosis of Erectile Dysfunction

E. Schaffort Promotion 2006 Hormonal manipulation in prostate cancer

Manuscriptcomissie

17-09-2014 dr. S. Lütje Titel proefschrift thesis Antibody-based imaging of prostate cancer

22-10-2013 dr. G.C. Koning Titel proefschrift Anterior Preperitorneal Inguinal Hernia Repair

Curriculum vitae


28-05-2013 dr. H.J.M. Meijer Titel proefschrift Magnetic resonance lymphography and lymph node irradiation in prostate cancer

11-04-2012 dr. R.Z.A.E.F. Mahfouz Titel proefschrift Oxidative stress and apoptotic biomarkers in human semen

17-03-2016 dr. A.R.H. Hamid Titel proefschrift Perzonalized treatment of castration resistant prostate cancer

24-06-2016 dr. C.M. van Rij Titel proefschrift(Pre)targeting of Prostate Cancer

04-07-2016 MSc. W.J.M. van de Ven Titel proefschritt: 'MRI guided TRUS prostate biopsy - a viable alternative?'

30-11-2016 dr. T.F.M. Vergeldt Titel proefschrift: Risk factors for pelvic organ prolapse recurrence and the role of findings on translabial ultrasound’

22-12-2016 dr. M.W.J. Stommel Titel proefschrift: Colorectal Surgery and adhesions

10-03-2017 drs. R. Krol Titel proefschrift: Anorectal toxicity after pelvic radiotherapy

06-07-2017 drs. M. de Rooij Titel proefschrift: Multiparametric MRI in prostate cancer: diagnostic accuracy and economic evaluation

07-07-2017 drs. S. Dijkstra Titel: Prostate cancer: urine- and blood-based biomarkers

Overige activiteiten

Inkomend voorzitter Bestuur NVU 2015-2017

Bestuursvoorzitter Centrum voor Oncologie

Chairman of the Research Foundation of the European Association of Urology 2008-2017

Advisory Board CML Kidney Cancer

Wetenschappelijke commissie European Association of Urology 2004-2008

Wetenschappelijke commissie Nederlandse Vereniging voor Urologie 2004-

Voorzitter EORTC GU Group, Kidney Cancer Disease Oriented Group

Voorzitter werkgroep Gen en Immunotherapie, Radboud Universiteit Nijmegen

Redactie Nederlands Tijdschrift voor Geneeskunde 2005-

Bestuur Nederlandse vereniging Gentherapie 2001-

Redactie Nederlands Tijdschrift voor Urologie (Sectie-editor wetenschappelijk gedeelte) 2002-

Radboud Leergang Integraal Management 2001-2002

Selecting editor Framingham in Urology 2007

Medical Advisory Board van de Kidney Cancer Journal International 2006- Lidmaatschappen

American Urological Association (AUA)

American Association for Cancer Research (AACR)

American Association of Genitourinary Surgeons (AAGUS)

Clinical Trials and Awards Committee UK

Dutch Guidelines committee renal cell carcinoma

EORTC-GU group (Chairman section Kidney Cancer)

Curriculum vitae


European Association of Urology (EAU) – Board member

European Association of Urology research foundation (EAUrf) - Chairman

Society for Biological Therapy

European Society for Medical Oncology

Society of Urology Oncology

Study group Immunotherapy, The Netherlands

Reviewer voor

Dutch Journal of Urology – editor

Dutch Cancer Society

European Urology

Framingham on Urology – editor

Journal of Urology

Kidney Cancer Journal International – editor in chief

Medical Advisory Board of the Kidney Cancer Journal International

World Journal of Urology – editor

Curriculum vitae - Radboud University Portal · Curriculum vitae 1 ... Smith MR, Saad F, Rathkopf...

Documents

Transcript of Curriculum vitae - Radboud University Portal · Curriculum vitae 1 ... Smith MR, Saad F, Rathkopf...